Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390362 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
A Phase 3 study, sponsored by Nationwide Children's Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3
- Enrollment target
NCT02390362 is a Phase 3 study that was terminated before completion, run by Nationwide Children's Hospital. The registered enrollment target is 3 participants.
The verdict
NCT02390362, a Phase 3 study, was terminated before completion, sponsored by Nationwide Children's Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3 participants
- Enrollment target
Study Summary
We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while receiving MMF. We will conduct a randomized study comparing two Rituximab infusions and continued MMF treatment. We plan to enroll 64 to have a comparater group of 58 (29 in each arm).
Interventions
- DRUG Rituximab
- DRUG MMF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-01-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390362
The ClinicalTrials.gov registry entry for NCT02390362 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02390362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390362 about?
NCT02390362 is a clinical study titled "Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome". We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while receiving MMF. We will conduct a randomized study comparing two Rituxim...
What is the current status of trial NCT02390362?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3 participants. The study started on 2015-01. Estimated completion is 2017-01-18.
What interventions are being tested in trial NCT02390362?
The interventions under investigation include: Rituximab (DRUG), MMF (DRUG).
Who is sponsoring clinical trial NCT02390362?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.